Tejara Capital’s Arcus Biosciences RCUS Stock Holding History

Tejara Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-50,000	Closed	-$912K	–	92
2023 Q1	$912K	Buy	+50,000	New	+$956K	0.47%	47

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Tejara Capital's RCUS Position: Q2 2023 in Review

Tejara Capital sold out of Arcus Biosciences (RCUS) in Q2 2023, closing a stake of 50,000 shares — an estimated $912K sold.

Tejara Capital first reported a position in RCUS in Q1 2023 and held it in 1 quarter. The position peaked at $912K in Q1 2023. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

Tejara Capital reported no remaining Arcus Biosciences position as of Q2 2023 after selling out during the quarter.
Tejara Capital sold 50,000 Arcus Biosciences shares in Q2 2023, an estimated $912K.
Tejara Capital first reported a position in Arcus Biosciences in Q1 2023 and held it in 1 quarter.
Tejara Capital's Arcus Biosciences position peaked at $912K in Q1 2023.
181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on Tejara Capital's 13F filing for Q2 2023, filed 11 Aug 2023.